Revenue and margins
Revenue was $4.2M, up 243.9% from $1.2M in the same period a year earlier, which ended Sep 30, 2025. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
The net loss was $39.0M. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
Balance sheet
Cash was $54.9M at Sep 30, 2026, against $47.5M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
Shares outstanding were 181.9 million, against 181.4 million at Jun 30, 2026, a rise of 0.3%. (SEC XBRL company facts, 10-Q, Nov 12, 2026)
At its recent quarterly burn of $39.4M, that cash lasts about 4.2 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
The stock
The Nasdaq screener puts its market value at $707.7M. (Nasdaq stock screener, Nov 13, 2026)
Prime Medicine Inc. sets up an at-the-market share program
The 424B5 that Prime Medicine Inc. (PRME) filed on Nov 10, 2026 describes an at-the-market program, in which an agent sells new shares into the market over time. (SEC EDGAR, 424B5, Nov 10, 2026)
Prime Medicine Inc. files for an at-the-market share sale
Prime Medicine Inc. (PRME) filed a 424B5 on Nov 12, 2026 whose text describes an at-the-market offering, shares sold into the market over time through a sales agent. (SEC EDGAR, 424B5, Nov 12, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/PRME)
The filing on SEC EDGAR. (sec.gov)
The filing in the MarginsX reader. (MarginsX reader)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.